Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB-WT) Shares Outstanding (Weighted Average) (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3129.94% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 3129.94% year-over-year, with the annual reading at $8.7 million for FY2025, 0.0% changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $8.7 million at Nuvation Bio, roughly flat from $8.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $8.7 million in Q3 2024, with the low at $218842.0 in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $4.7 million, with a median of $5.8 million recorded in 2023.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 3866.87% in 2024, while the deepest fall reached 96.22% in 2024.
  • Over 3 years, Shares Outstanding (Weighted Average) stood at $218880.0 in 2023, then rose by 22.79% to $268772.0 in 2024, then surged by 3129.94% to $8.7 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $8.7 million, $8.7 million, and $8.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.